View Item 

Show simple item record

The Association Between the Use of Zolpidem and the Risk of Alzheimer’s Disease Among Older People
dc.contributor.authorCheng, Hui‐ting
dc.contributor.authorLin, Fang‐ju
dc.contributor.authorErickson, Steven R.
dc.contributor.authorHong, Jin‐liern
dc.contributor.authorWu, Chung‐hsuen
dc.date.accessioned2017-12-15T16:48:27Z
dc.date.available2019-01-07T18:34:37Zen
dc.date.issued2017-11
dc.identifier.citationCheng, Hui‐ting ; Lin, Fang‐ju ; Erickson, Steven R.; Hong, Jin‐liern ; Wu, Chung‐hsuen (2017). "The Association Between the Use of Zolpidem and the Risk of Alzheimer’s Disease Among Older People." Journal of the American Geriatrics Society 65(11): 2488-2495.
dc.identifier.issn0002-8614
dc.identifier.issn1532-5415
dc.identifier.urihttps://hdl.handle.net/2027.42/140000
dc.publisherOvation Research Group
dc.publisherWiley Periodicals, Inc.
dc.subject.otherhypnotics
dc.subject.otherNational Health Insurance Research Database (NHIRD)
dc.subject.otherAlzheimer’s disease
dc.subject.otherzolpidem
dc.subject.otherTaiwan
dc.titleThe Association Between the Use of Zolpidem and the Risk of Alzheimer’s Disease Among Older People
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelGeriatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/140000/1/jgs15018_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/140000/2/jgs15018.pdf
dc.identifier.doi10.1111/jgs.15018
dc.identifier.sourceJournal of the American Geriatrics Society
dc.identifier.citedreferencePuar TH, Khoo JJ, Cho LW et al. Association between glycemic control and hip fracture. JAGS 2012; 60: 1493 â 1497.
dc.identifier.citedreferenceMinistry of Health and Welfare. National Health Informatics Project, NHIP. Available at http://www.mohw.gov.tw/cht/DOS/DM1_P.aspx?f_list_no=812&fod_list_no=4788&doc_no=43639. 2015. Accessed on July 1, 2016.
dc.identifier.citedreferenceWHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/. Accessed on May 9, 2017.
dc.identifier.citedreferenceYang YW, Hsieh TF, Yu CH et al. Zolpidem and the risk of Parkinson’s disease: a nationwide populationâ based study. J Psychiatr Res 2014; 58: 84 â 88.
dc.identifier.citedreferenceBallard C, Gauthier S, Corbett A et al. Alzheimer’s disease. Lancet 2011; 377: 1019 â 1031.
dc.identifier.citedreferenceWu CS, Ting TT, Wang SC et al. Effect of benzodiazepine discontinuation on dementia risk. Am J Geriatr Psychiatry 2011; 19: 151 â 159.
dc.identifier.citedreferenceChou CY, Chou YC, Chou YJ et al. Statin use and incident dementia: a nationwide cohort study of Taiwan. Int J Cardiol 2014; 173: 305 â 310.
dc.identifier.citedreferenceGeerlings MI, Schoevers RA, Beekman AT et al. Depression and risk of cognitive decline and Alzheimer’s disease. Results of two prospective communityâ based studies in The Netherlands. Br J Psychiatry 2000; 176: 568 â 575.
dc.identifier.citedreferenceOwnby RL, Crocco E, Acevedo A et al. Depression and risk for Alzheimer disease: systematic review, metaâ analysis, and metaregression analysis. Arch Gen Psychiatry 2006; 63: 530 â 538.
dc.identifier.citedreferenceBrookhart MA, Wyss R, Layton JB et al. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes 2013; 6: 604 â 611.
dc.identifier.citedreferenceParsons LS. Reducing Bias in a Propensity Score Matchedâ Pair Sample UsingGreedy Matching Techniques. Cary, NC: Ovation Research Group; 2001.
dc.identifier.citedreferenceChen PL, Lee WJ, Sun WZ et al. Risk of dementia in patients with insomnia and longâ term use of hypnotics: a populationâ based retrospective cohort study. PLoS ONE 2012; 7: e49113.
dc.identifier.citedreferencePatorno E, Patrick AR, Garry EM et al. Observational studies of the association between glucoseâ lowering medications and cardiovascular outcomes: addressing methodological limitations. Diabetologia 2014; 57: 2237 â 2250.
dc.identifier.citedreferenceLund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep 2015; 2: 221 â 228.
dc.identifier.citedreferenceCheng JS, Huang WF, Lin KM et al. Characteristics associated with benzodiazepine usage in elderly outpatients in Taiwan. Int J Geriatr Psychiatry 2008; 23: 618 â 624.
dc.identifier.citedreferenceFetveit A, Bjorvatn B. Sleep disorders in the elderly. Tidsskr Nor Laegeforen 2009; 129: 2004 â 2006.
dc.identifier.citedreferenceFick DM, Semla TP, Beizer J et al. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015; 63: 2227 â 2246.
dc.identifier.citedreferenceAlzheimers Association. 2014 Alzheimer’s disease facts and figures. Alzheimers Dement 2014; 10: e47 â e92.
dc.identifier.citedreferenceGreco A, Cascavilla L, Paris F et al. Undercoding of Alzheimer’s disease and related dementias in hospitalized elderly patients in Italy. Am J Alzheimers Dis Other Demen 2005; 20: 167 â 170.
dc.identifier.citedreferenceFillit H, Geldmacher DS, Welter RT et al. Optimizing coding and reimbursement to improve management of Alzheimer’s disease and related dementias. J Am Geriatr Soc 2002; 50: 1871 â 1878.
dc.identifier.citedreferenceChen Jâ H, Lin Kâ P, Chen Yâ C. Risk factors for dementia. J Formos Med Assoc 2009; 108: 754 â 764.
dc.identifier.citedreferenceKarve S, Cleves MA, Helm M et al. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008; 46: 1125 â 1133.
dc.identifier.citedreferenceKarve S, Cleves MA, Helm M et al. Good and poor adherence: optimal cutâ point for adherence measures using administrative claims data. Curr Med Res Opin 2009; 25: 2303 â 2310.
dc.identifier.citedreferenceKumar A, Singh A. Ekavali. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep 2015; 67: 195 â 203.
dc.identifier.citedreferenceOboudiyat C, Glazer H, Seifan A et al. Alzheimer’s disease. Semin Neurol 2013; 33: 313 â 329.
dc.identifier.citedreferenceDementia. World Health Organization. Available at http://www.who.int/mediacentre/factsheets/fs362/en/. Accessed on August 14, 2017.
dc.identifier.citedreferenceBerdyyeva T, Otte S, Aluisio L et al. Zolpidem reduces hippocampal neuronal activity in freely behaving mice: a large scale calcium imaging study with miniaturized fluorescence microscope. PLoS ONE 2014; 9: e112068.
dc.identifier.citedreferenceStatistical Yearbook of Interior. Available at http://sowf.moi.gov.tw/stat/year/list.htm. 2014. Accessed on January 1, 2015.
dc.identifier.citedreferenceTaiwan Dementia Policy A Framework for Prevention and Care. Available at https://www.slideshare.net/OpenMic1/20141224-42978044. Accessed on December 24, 2014.
dc.identifier.citedreferenceDementia: a public health priority. Availabe at http://www.who.int/mental_health/publications/dementia_report_2012/en/. 2012. Accessed on March 1, 2017.
dc.identifier.citedreferenceGreenblatt DJ, Roth T. Zolpidem for insomnia. Expert Opin Pharmacother 2012; 13: 879 â 893.
dc.identifier.citedreferenceHolm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000; 59: 865 â 889.
dc.identifier.citedreferenceMacFarlane J, Morin CM, Montplaisir J. Hypnotics in insomnia: the experience of zolpidem. Clin Ther 2014; 36: 1676 â 1701.
dc.identifier.citedreferenceYen CF, Yen CN, Ko CH et al. Correlates of dependence and beliefs about the use of hypnotics among zolpidem and zopiclone users. Subst Use Misuse 2015; 50: 350 â 357.
dc.identifier.citedreferenceLu TH, Lee YY, Lee HC et al. Doctor shopping behavior for zolpidem among insomnia patients in taiwan: a nationwide populationâ based study. Sleep 2015; 38: 1039 â 1044.
dc.identifier.citedreferenceSancar F, Ericksen SS, Kucken AM et al. Structural determinants for highâ affinity zolpidem binding to GABAâ A receptors. Mol Pharmacol 2007; 71: 38 â 46.
dc.identifier.citedreferenceTannenbaum C, Paquette A, Hilmer S et al. A systematic review of amnestic and nonâ amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 2012; 29: 639 â 658.
dc.identifier.citedreferencePat McAndrews M, Weiss RT, Sandor P et al. Cognitive effects of longâ term benzodiazepine use in older adults. Hum Psychopharmacol 2003; 18: 51 â 57.
dc.identifier.citedreferenceLagnaoui R, Begaud B, Moore N et al. Benzodiazepine use and risk of dementia: a nested caseâ control study. J Clin Epidemiol 2002; 55: 314 â 318.
dc.identifier.citedreferenceBillioti de Gage S, Begaud B, Bazin F et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ 2012; 345: e6231.
dc.identifier.citedreferenceGallacher J, Elwood P, Pickering J et al. Benzodiazepine use and risk of dementia: evidence from the caerphilly prospective study (CaPS). J Epidemiol Community Health 2012; 66: 869 â 873.
dc.identifier.citedreferenceWu CS, Wang SC, Chang IS et al. The association between dementia and longâ term use of benzodiazepine in the elderly: nested caseâ control study using claims data. Am J Geriatr Psychiatry 2009; 17: 614 â 620.
dc.identifier.citedreferenceShih HI, Lin CC, Tu YF et al. An increased risk of reversible dementia may occur after zolpidem derivative use in the elderly population: a populationâ based caseâ control study. Medicine (Baltimore) 2015; 94: e809.
dc.identifier.citedreferenceBillioti de Gage S, Moride Y, Ducruet T et al. Benzodiazepine use and risk of Alzheimer’s disease: caseâ control study. BMJ 2014; 349: g5205.
dc.identifier.citedreferenceHealth and Welfare Data Science Center. Introduction of the Database. Available at https://www.mohw.gov.tw/mp-1.html. 2015. Accessed on July 1, 2016
dc.identifier.citedreferenceHsing AW, Ioannidis JP. Nationwide population science: lessons from the Taiwan national health insurance research database. JAMA Intern Med 2015; 175: 1527 â 1529.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jgs15018_am.pdf
Size:
247.0KB
Format:
PDF
View/Open
Name:
jgs15018.pdf
Size:
145.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.